The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes
Authors' conclusion
Adding either exenatide or lispro to basal insulin therapy does not appear to affect fasting endothelial function in early T2DM.
Study context
- Population
- Adults with T2D of < 7-years duration
- Participants
- 24 / 24 / 25
- Comparison
- Glargine + exenatide vs glargine + lispro vs glargine alone
- Glargine (Glar)n = 24reference
- Glar/Lispron = 24
- Glar/Exenatiden = 25
- Primary endpoint
- Fasting endothelial function: RHI by peripheral arterial tonometry
- Follow-up
- 8-weeks
Methodological detailsthree-arm, 20-week trial with 12-week washout
- Three-arm
- 20-week trial with 12-week washout
Primary result
As reported in the abstract
Baseline-adjusted fasting RHI (endothelial function) · 8 weeks
Glar
2.07
mean · SE 0.10
Glar/Lispro
2.00
mean · SE 0.10
Glar/Exenatide
1.81
mean · SE 0.10
P = 0.19
Further findings
| Outcome | Glar/Exenatide |
|---|---|
| Systolic BP change from baseline with Glar/Exenatide · 8-weeks | mean - 8.1 (CI - 13.9 to - 2.4) mmHg |
| P | p = 0.008 |
| Diastolic BP change from baseline with Glar/Exenatide · 8-weeks | mean - 5.1 (CI - 9.0 to - 1.3) mmHg |
| P | p = 0.012 |
Baseline-adjusted blood pressure (BP) and HR between groups · 8-weeks
- Baseline-adjusted BP and HR did not differ between the groups
Baseline-adjusted reactive hyperemia index (RHI), BP and HR after washout · 12-weeks washout
- No differences between the groups
Original publication
The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes. Cardiovasc Diabetol. Published 9 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →